Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 1999; 33:46-52
© 1999 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kühlkamp, V.
Right arrow Articles by Seipel, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kühlkamp, V.
Right arrow Articles by Seipel, L.

CLINICAL STUDIES

Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment

Volker Kühlkamp, MDa, Christian Mewis, MDa, Johannes Mermi, MDa, Ralph F. Bosch, MDa and Ludger Seipel, MDa

a Eberhard-Karls-University, Medical Department III, Tübingen, Germany

Manuscript received October 28, 1997; revised manuscript received August 11, 1998, accepted September 23, 1998.

Address for correspondence: Dr. Volker Kühlkamp, Eberhard-Karls-Universität, Medizinische Klinik III, Otfried Müller Str. 10, 72076 Tübingen, Germany
Volker.Kuehlkamp{at}uni-tuebingen.de

Objectives. This study evaluates the clinical efficacy of d,l-sotalol in patients with sustained ventricular tachyarrhythmias.

Background. D,l-sotalol is an important antiarrhythmic agent to prevent recurrences of sustained ventricular tachyarrhythmias (VT/VF). However, evidence is lacking that an antiarrhythmic agent like d,l-sotalol can reduce the incidence of sustained ventricular tachyarrhythmias in comparison to no antiarrhythmic drug treatment.

Methods. A prospective study was performed in 146 consecutive patients with inducible sustained ventricular tachycardia or ventricular fibrillation. In 53 patients, oral d,l-sotalol prevented induction of VT/VF during electrophysiological testing and patients were discharged on oral d,l-sotalol (sotalol group). In 93 patients, VT/VF remained inducible and a defibrillator (ICD) was implanted. After implantation of the device patients were randomly assigned to oral treatment with d,l-sotalol (ICD/sotalol group, n = 46) or no antiarrhythmic medication (n = 47, ICD-only group).

Results. During follow-up, 25 patients (53.2%) in the ICD-only group had a VT/VF recurrence in comparison to 15 patients (28.3%) in the sotalol group and 15 patients (32.6%) in the ICD/sotalol group (p = 0.0013). Therapy with d,l-sotalol, amiodarone or metoprolol was instituted in 12 patients (25.5%) of the ICD-only group due to frequent VT/VF recurrences or symptomatic supraventricular tachyarrhythmias. In nine patients, 17% of the sotalol group, an ICD was implanted after VT/VF recurrence, three patients (5.7%) received amiodarone. Total mortality was not different between the three groups.

Conclusions. D,l-sotalol significantly reduces the incidence of recurrences of sustained ventricular tachyarrhythmias in comparison to no antiarrhythmic drug treatment.

Abbreviations and Acronyms
  VT/VF = sustained ventricular tachyarrhythmias
  ICD = implantable cardioverter defibrillator




This article has been cited by other articles:


Home page
Mayo Clin Proc.Home page
B. A. Koplan and W. G. Stevenson
Ventricular Tachycardia and Sudden Cardiac Death
Mayo Clin. Proc., March 1, 2009; 84(3): 289 - 297.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
I. Ferreira-Gonzalez, L. Dos-Subira, and G. H. Guyatt
Adjunctive antiarrhythmic drug therapy in patients with implantable cardioverter defibrillators: a systematic review
Eur. Heart J., February 2, 2007; 28(4): 469 - 477.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
A. K. Gehi, D. Mehta, and J. A. Gomes
Evaluation and Management of Patients After Implantable Cardioverter-Defibrillator Shock
JAMA, December 20, 2006; 296(23): 2839 - 2847.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
Developed in Collaboration With the European Heart, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al.
ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death)
J. Am. Coll. Cardiol., September 5, 2006; 48(5): e247 - e346.
[Full Text] [PDF]


Home page
EuropaceHome page
Writing Committee Members, D. P. Zipes, A. J. Camm, M. Borggrefe, A. E. Buxton, B. Chaitman, M. Fromer, G. Gregoratos, G. Klein, A. J. Moss, et al.
ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Europace, September 1, 2006; 8(9): 746 - 837.
[Full Text] [PDF]


Home page
NEJMHome page
P. J. Podrid
Redefining the Role of Antiarrhythmic Drugs
N. Engl. J. Med., June 17, 1999; 340(24): 1910 - 1912.
[Full Text]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement